Invention Application
- Patent Title: Therapeutic Vaccine for Hepatitis B Virus (HBV) using the HBV Core Antigen
-
Application No.: US17721554Application Date: 2022-04-15
-
Publication No.: US20220241403A1Publication Date: 2022-08-04
- Inventor: Edward A. CLARK , Deborah L. FULLER , Che-Leung LAW , Amanda MAK
- Applicant: UNIVERSITY OF WASHINGTON , ABACUS BIOSCIENCE, INC.
- Applicant Address: US WA Seattle; US WA Sammamish
- Assignee: UNIVERSITY OF WASHINGTON,ABACUS BIOSCIENCE, INC.
- Current Assignee: UNIVERSITY OF WASHINGTON,ABACUS BIOSCIENCE, INC.
- Current Assignee Address: US WA Seattle; US WA Sammamish
- Main IPC: A61K39/29
- IPC: A61K39/29 ; A61K39/00 ; A61K39/39 ; C07K16/28 ; C12N7/00
Abstract:
Provided herein are compositions of CD1280 binding proteins and a Hepatitis B virus core antigen (HBcAg) and/or a Hepatitis B virus E antigen (HBeAg), or antigenic fragments or mutants thereof, attached to the CD180 binding protein, and methods for using the compositions to treat or limit the development of hepatitis-B virus (HBV)-related disorders.
Public/Granted literature
- US11883488B2 Therapeutic vaccine for Hepatitis B virus (HBV) using the HBV core antigen Public/Granted day:2024-01-30
Information query
